That's the end of regulation. X-Trackers by DWS, ringing the closing belt, the New York Stock Exchange,

Lobshit, Lobsack company, not Lobsack, doing the honors at the NASDAG. The Dow finishing lower for the

ninth straight session. This is the longest losing streak since 1978 for the Dow Industrials.

As attention turns to tomorrow's Fed decision, that's the scorecard on Wall Street, but the action

is just getting started. Welcome to closing bell overtime. I'm Morgan Brennan with John Ford.

And coming up on today's show, InVIDIA falls deeper into correction territory. We'll ask an analyst

if this is the buying opportunity you've been waiting for or if more pain is ahead.

Plus, a number of big moves in the pharma space today, including a pop for Pfizer and a 25%

surge for another big player.

We're going to discuss the best buys in the space heading into your end.

And an under the radar defense winner.

Shares of Parsons are up more than 50% this year, but will the Department of Government

Efficiency put the

brakes on that rally? Parsons CEO joins us to discuss.

And let's get straight to the market action with I Capital Chief Investment Strategist,

Anastasia Emeroso, and Bespoke Investment Group co-founder Paul Hickey.

Welcome to you both.

Another down day for the markets.

Anastasia, I'm going to start with you.

We've had poor breath. We've got what's expected to be a, I'll say, hawkish-fed pivot, or at least a slowing pace of easing with the FOMC rate decision tomorrow.

You've got sentiment and positioning that's particularly frothy and then risks factoring into the market around what Trump 2.0 is going to mean

here for stocks. Yeah. How do you see 2025? Well, 2025 is definitely a positive story. And I can talk

...